REZILIENT3: Phase 3 study of zipalertinib plus chemotherapy in patients with previously untreated, advanced nonsquamous non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertions (ex20ins) mutations.

Authors

Helena Alexandra Yu

Memorial Sloan Kettering Cancer Center, New York, NY

Helena Alexandra Yu , Benjamin Besse , Makoto Nishio , Ying Cheng , Li Wei , Volker Wacheck , John Heymach

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

A phase II study of osimertinib in combination with platinum plus pemetrexed in patients with EGFR-mutated, advanced non–small cell lung cancer: The OPAL study (NEJ032C/LOGIK1801).

First Author: Atsushi Nakamura

insert_chart_outlined

Poster

2014 ASCO Annual Meeting

bookmark_border

First-line crizotinib versus pemetrexed–cisplatin or pemetrexed–carboplatin in patients (pts) with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC): results of a phase III study (PROFILE 1014)

First Author: Tony Mok

insert_chart_outlined

Poster

2011 ASCO Annual Meeting

bookmark_border

Updated efficacy and quality of life (QoL) analyses in OPTIMAL, a phase III, randomized, open-label study of first-line erlotinib vs gemcitabine/carboplatin in patients with EGFR activating-mutation positive (EGFR Act Mut+) advanced non-small cell lung cancer (NSCLC).

First Author: C. Zhou

insert_chart_outlined

Poster

2024 ASCO Annual Meeting

bookmark_border

A phase 1b study of ensartinib in combination with platinum-based chemotherapy and bevacizumab in ALK-positive non-small cell lung cancer (NSCLC).

First Author: Kyle Concannon